There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin (NASDAQ:BMRN) and Boston Scientific Corp (NYSE:BSX) with bullish sentiments.
BioMarin (BMRN)
Raymond James analyst Laura Chico maintained a Buy rating on BioMarin today and set a price target of $114. The company’s shares opened today at $90.
According to TipRanks.com, Chico is a 1-star analyst with an average return of -2.2% and a 44.7% success rate. Chico covers the Healthcare sector, focusing on stocks such as Dova Pharmaceuticals Inc, Paratek Pharmaceuticals, and Vertex Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioMarin with a $119.17 average price target, a 32.4% upside from current levels. In a report issued on October 16, Jefferies also maintained a Buy rating on the stock with a $125 price target.
.
See today’s analyst top recommended stocks >>
Boston Scientific Corp (BSX)
Argus Research analyst Jasper Hellweg maintained a Buy rating on Boston Scientific Corp today and set a price target of $43. The company’s shares opened today at $35.95.
According to TipRanks.com, Hellweg is a 2-star analyst with an average return of 3.2% and a 47.1% success rate. Hellweg covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Perrigo Company plc, and Ligand Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific Corp with a $42.13 average price target, implying a 17.2% upside from current levels. In a report issued on October 15, Barclays also initiated coverage with a Buy rating on the stock.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
